<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS96492</article-id>
<article-id pub-id-type="doi">10.1101/2020.09.28.316604</article-id>
<article-id pub-id-type="archive">PPR219868</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Host transcriptomic profiling of COVID-19 patients with mild, moderate, and severe clinical outcomes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Jain</surname>
<given-names>Ruchi</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ramaswamy</surname>
<given-names>Sathishkumar</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Harilal</surname>
<given-names>Divinlal</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Uddin</surname>
<given-names>Mohammed</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Loney</surname>
<given-names>Tom</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nowotny</surname>
<given-names>Norbert</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alsuwaidi</surname>
<given-names>Hanan</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Varghese</surname>
<given-names>Rupa</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Deesi</surname>
<given-names>Zulfa</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alkhajeh</surname>
<given-names>Abdulmajeed</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Khansaheb</surname>
<given-names>Hamda</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alsheikh-Ali</surname>
<given-names>Alawi</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tayoun</surname>
<given-names>Ahmad Abou</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Al Jalila Genomics Center, Al Jalila Children's Hospital, Dubai, United Arab Emirates</aff>
<aff id="A2">
<label>2</label>College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates</aff>
<aff id="A3">
<label>3</label>The Centre for Applied Genomics (TCAG), The Hospital for Sick Children, Toronto, ON, Canada</aff>
<aff id="A4">
<label>4</label>Institute of Virology, University of Veterinary Medicine Vienna, Vienna, Austria</aff>
<aff id="A5">
<label>5</label>Microbiology and Infection Control Unit, Pathology and Genetics Department, Latifa Women and Children Hospital, Dubai Health Authority, Dubai, United Arab Emirates</aff>
<aff id="A6">
<label>6</label>Medical Education &amp; Research Department, Dubai Health Authority, Dubai, United Arab Emirates</aff>
<author-notes>
<corresp id="CR1">
<label>*</label>Corresponding Author: Ahmad Abou Tayoun (<email>Ahmad.Tayoun@ajch.ae</email>)</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>30</day>
<month>09</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="preprint">
<day>28</day>
<month>09</month>
<year>2020</year>
</pub-date>
<permissions>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">Characterizing key molecular and cellular pathways involved in COVID-19 is essential for disease prognosis and management. We perform shotgun transcriptome sequencing of human RNA obtained from nasopharyngeal swabs of patients with COVID-19, and identify a molecular signature associated with disease severity. Specifically, we identify globally dysregulated immune related pathways, such as cytokine-cytokine receptor signaling, complement and coagulation cascades, JAK-STAT, and TGF-β signaling pathways in all, though to a higher extent in patients with severe symptoms. The excessive release of cytokines and chemokines such as <italic>CCL2</italic>, <italic>CCL22</italic>, <italic>CXCL9</italic> and <italic>CXCL12</italic> and certain interferons and interleukins related genes like <italic>IFIH1</italic>, <italic>IFI44</italic>, <italic>IFIT1</italic> and <italic>IL10</italic> were significantly higher in patients with severe clinical presentation compared to mild and moderate presentations. Moreover, early induction of the TGF-β signaling pathway might be the primary cause of pulmonary fibrosis in patients with severe disease. Differential gene expression analysis identified a small set of regulatory genes that might act as strong predictors of patient outcome. Our data suggest that rapid transcriptome analysis of nasopharyngeal swabs can be a powerful approach to quantify host molecular response and may provide valuable insights into COVID-19 pathophysiology.</p>
</abstract>
<kwd-group>
<kwd>Host Transcriptome</kwd>
<kwd>COVID-19</kwd>
<kwd>Clinical Outcomes</kwd>
<kwd>Sequenicng</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P2">Since the first case reported in December 2019 in Wuhan, SARS-CoV-2 has spread very quickly across 188 different countries leading to over 31,887,485 COVID-19 cases and 976,789 associated deaths worldwide as of 24<sup>th</sup> September 2020.<sup>
<xref ref-type="bibr" rid="R1">1</xref>
</sup> The common signs and symptoms of SARS-CoV-2 include fever, cough, fatigue, shortness of breath, and chest CT abnormalities.<sup>
<xref ref-type="bibr" rid="R2">2</xref>
</sup> Some patients with COVID-19 quickly develop severe pulmonary symptoms including acute respiratory distress syndrome (ARDS), pulmonary edema, intense kidney injury and multiple organ failure<sup>
<xref ref-type="bibr" rid="R3">3</xref>
</sup> whereas other patients present with no symptoms or with only mild disease.<sup>
<xref ref-type="bibr" rid="R4">4</xref>
</sup> Pathogen load and prevalence of infections are higher in males than females demonstrating that sex physiology plays a role in infectious disease pathogenesis.<sup>
<xref ref-type="bibr" rid="R5">5</xref>
</sup> Meng and colleagues<sup>
<xref ref-type="bibr" rid="R6">6</xref>
</sup> showed that men who died of COVID-19 had elevated levels of systemic inflammatory markers such as neutrophil-to-lymphocyte ratio and C-reactive protein. Nevertheless, the mechanism behind increased mortality among older adults and males with COVID-19 remains speculative.</p>
<p id="P3">Despite the worldwide spreading, the host immune response against SARS-CoV-2 infection remains poorly characterized. Dysregulation of host immune response and activation of inflammatory cytokines, known as the "cytokine storm", is associated with disease severity and poor prognosis.<sup>
<xref ref-type="bibr" rid="R7">7</xref>, <xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R9">9</xref>
</sup> A recent host transcriptome study on patients with COVID-19 revealed distinct host inflammatory cytokine profiles and highlighted the association between SARS-CoV-2 pathogenesis and excessive release of cytokine such as CCL2/MCP-1, CXCL10/IP-10, CCL3/MIP-1A, and CCL4/MIP1B.<sup>
<xref ref-type="bibr" rid="R10">10</xref>
</sup> Additionally, Lieberman <italic>et al.</italic> showed upregulation of antiviral factors such as OAS1-3 and IFIT1-3, and Th1 chemokines CXCL9/10/11 upon SARS-CoV2 induced antiviral response. This study also showed immune responses may underlie disparities between males and females, and among the elderly compared to younger age groups.<sup>
<xref ref-type="bibr" rid="R11">11</xref>
</sup>
</p>
<p id="P4">At present, it is not known if the host gene expression profile varies among patients with mild, moderate, or severe clinical outcomes. Identification of such transcriptomic differences can be useful for predicting COVID-19 outcomes and for better management and earlier interventions especially for patient groups with severe outcomes. In this study, we performed RNA sequencing on nasopharyngeal tissue of patients with mild, moderate, and severe disease to characterize transcriptomic regulation and immune response differences among these patients, and to identify markers for early identification of patients with possible severe disease outcomes.</p>
</sec>
<sec id="S2" sec-type="methods">
<title>Methods</title>
<sec id="S3">
<title>Patient cohort and ethics statement</title>
<p id="P5">This study was approved by the Dubai Scientific Research Ethics Committee - Dubai Health Authority (approval number #DSREC-04/2020_02). The Ethics committee waived the requirement for informed consent since this study was part of a public health surveillance and outbreak investigation in the UAE. The electronic medical records of patients with laboratory confirmed SARS-CoV-2 were reviewed and important clinical data were extracted using the World Health Organization (WHO) case report form.</p>
</sec>
<sec id="S4">
<title>Sample preparation, RNA isolation, library construction and sequencing</title>
<p id="P6">RNA was extracted from nasopharyngeal swabs using the QIAamp Viral RNA Mini or the 213 EZ1 DSP Virus Kits (Qiagen, Hilden, Germany). All patients in this study tested positive for SARS-CoV-2 by RT-qPCR performed at Dubai Health Authority Hospitals. RNA libraries were then prepared for shotgun transcriptome sequencing using the TruSeq Stranded Total RNA Library kit from Illumina (San Diego, CA, USA) as previously described.<sup>
<xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R14">14</xref>
</sup> Libraries were then sequenced using the NovaSeq SP Reagent kit (2 X 150 cycles) from Illumina (San Diego, CA, USA) to generate a minimum of 15M reads per sample (<xref ref-type="supplementary-material" rid="SD2">Supplementary Table 1</xref>).</p>
</sec>
<sec id="S5">
<title>Data analysis</title>
<p id="P7">The sequencing read quality was checked using FastQC v0.11.8<sup>
<xref ref-type="bibr" rid="R15">15</xref>
</sup> and MultiQC v1.6.<sup>
<xref ref-type="bibr" rid="R16">16</xref>
</sup> High quality reads (Q ≥ 30) were first mapped to rRNA sequences to remove potential rRNA reads using hisat v2-2.1.0<sup>
<xref ref-type="bibr" rid="R17">17</xref>
</sup> with the default parameter. The remaining reads were then mapped to the GRCh37 (hg19). The unmapped reads were then mapped to the SARS-CoV-2 genome (GenBank Accession number: NC_045512.2) using BWA v0.7.17. PCR duplicates were removed with Picard MarkDuplicates program v2.18.17.<sup>
<xref ref-type="bibr" rid="R18">18</xref>
</sup> Samples with more than 6M reads aligned to the GRCh37 (hg19) were considered for further analysis. RNA sequencing data obtained from nasopharyngeal swabs of samples confirmed to be COVID-19 negative by RT-11 qPCR, hereafter referred to as controls (n = 32), were downloaded from GSE152075.<sup>
<xref ref-type="bibr" rid="R11">11</xref>
</sup>
</p>
<p id="P8">The number of reads mapped to each gene in the genome (GRCh37) was calculated using the FeatureCounts program in the SubReads package v2.0.1.<sup>
<xref ref-type="bibr" rid="R19">19</xref>
</sup> DESeq2 package v1.28.1<sup>
<xref ref-type="bibr" rid="R20">20</xref>
</sup> was applied to perform batch effects and normalization. In brief, DESeq2 uses the median of ratios method to normalize data and estimate size factors (which control for differences in the library size of the sequencing experiment). Further, gene expression change was calculated with respect to control for each groups using Wald test and <italic>p-</italic> values and log<sub>2</sub> fold change was extracted. The resulting genes <italic>p</italic>-value was adjusted using the Benjamini and Hochberg method. These adjusted <italic>p</italic>-value (adj <italic>p-</italic> value) are calculated as: gene <italic>p</italic>-value × (m/i)) where <italic>m</italic> is the total number of genes, <italic>i</italic> is the gene <italic>p</italic>-value rank. Here we have considered a fraction of 5% false positives acceptable hence the genes with adj <italic>p</italic>-value &lt; 0.05 were called as significant.</p>
<p id="P9">Pathway enrichment analysis was performed using the clusterProfiler package v 3.16.0<sup>
<xref ref-type="bibr" rid="R21">21</xref>
</sup> to identify shared pathways among DEGs. Pathways with adj <italic>p</italic>-value &lt; 0.05 were reported as significant. Heatmaps were generated using Morpheus<sup>
<xref ref-type="bibr" rid="R22">22</xref>
</sup> and volcano plots were generated using VolcaNoseR package.<sup>
<xref ref-type="bibr" rid="R23">23</xref>
</sup> Both case and control sequencing data were normalized to counts per million (CPM), which is calculated by normalizing the read counts for a given gene by the total counts per sample. CPM values were used to compare expression between certain genes and violin plots were generated using GraphPad Prism v8.0. <sup>
<xref ref-type="bibr" rid="R24">24</xref>
</sup> Two tailed Mann–Whitney U test <italic>P</italic>-values are reported. A schematic illustration of data analysis is represented in <xref ref-type="fig" rid="F1">Figure 1</xref>.</p>
</sec>
</sec>
<sec id="S6" sec-type="results">
<title>Results</title>
<sec id="S7">
<title>Patient Cohort</title>
<p id="P10">Our patient cohort consisted of fifty patients with COVID-19 (36% female) who tested positive for SARS-CoV-2 by RT-qPCR with a mean age of 40.9 years (ranging from 3 – 70 years) at diagnosis. Cases were categorized into mild, moderate, and severe as previously described.<sup>
<xref ref-type="bibr" rid="R12">12</xref>
</sup> Briefly, mild cases were asymptomatic or had mild non-life-threatening symptoms, while moderate cases presented with symptoms (such as persistent fever) requiring medical attention and/or hospitalization. Severe cases presented with advanced disease and pneumonia requiring admission to intensive care units and life-support treatment (such as mechanical ventilation). In total, 37 patients (21 males and 16 females; mean age 36.4 years) had mild disease, 10 patients (9 males and 1 female; mean age 49.3 years) had moderate presentations, while 3 patients (2 males and 1 female; mean age 68.0 years) had severe/critical disease. All patients were non-smokers. All 3 patients with severe disease had chronic health issues (hypertension, chronic kidney disease and/or diabetes mellitus) (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
</sec>
<sec id="S8">
<title>Global transcriptomic changes in patients with COVID-19</title>
<p id="P11">To understand the host mechanisms of SARS-CoV-2 infections, we explored transcriptomic profiling of patients with COVID-19 using RNA extracted from nasopharyngeal samples (see <xref ref-type="sec" rid="S2">Methods</xref>). We first mapped high quality reads to the human genome and the SARS-CoV-2 genome (GenBank accession number: NC_045512.2) and summarized sequencing statistics in <xref ref-type="supplementary-material" rid="SD2">Supplementary Table 1</xref>. On average, ~2% (ranging from 0.1% - 13.6%) of the reads mapped to the SARS-CoV-2 genome confirming the presence of the virus, albeit coverage over the viral genome varied across patients most likely due to differences in viral loads. On the other hand, ~65% (ranges from 24.3% - 91.0%) of the RNA reads mapped to the human genome, enabling host transcriptomic analysis.</p>
<p id="P12">To detect global signature genes in patients with COVID-19 we combined transcriptomic data from patients with mild, moderate, and severe disease and made a comprehensive cohort called “COVID” to compare against controls for DEG analysis (see <xref ref-type="sec" rid="S2">Methods</xref>). We detected 3572 upregulated genes and 445 downregulated genes with adj <italic>p</italic>-value◻&lt;◻0.05 and foldchange◻cutoff &gt;◻2. Several interferon, cytokine and immune-related genes, such as <italic>CXCL5</italic>, <italic>CXCL12</italic>, <italic>CCL2</italic>, <italic>IFIH1</italic>, <italic>IFI44</italic>, <italic>IFIT1</italic> and <italic>IL10</italic> were upregulated, whereas metabolic pathways or housekeeping genes, like <italic>RPL41</italic>, <italic>RPL17</italic>, <italic>SLC25A6</italic>, <italic>CALM1</italic> and <italic>TUBA1A</italic>, were downregulated (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p>
<p id="P13">Pathway enrichment analysis of the DEGs was performed to interrogate signaling programs induced by SARS-CoV-2. Up-regulated genes were related to cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, complement and coagulation cascades and other inflammatory pathways. Whereas, several metabolic pathways were negatively enriched, including ribosome, oxidative phosphorylation and ER protein processing, which suggests a global reduction in the production of proteins related to cellular energy production (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p>
</sec>
<sec id="S9">
<title>Transcriptome analysis of patients with mild, moderate and severe COVID-19</title>
<p id="P14">Next, we compared the transcriptomic profiles of patients with mild, moderate, and severe disease each separately with controls to determine if the above global signature, and the identified cytokine storm, hold similarly or varies by disease severity. Overall, we detected 2240 upregulated and 422 downregulated genes in mildly, 3447 upregulated and 302 downregulated genes in moderately, and 2691 upregulated and 215 downregulated genes in severely ill patient samples. Most of the immune response genes were significantly upregulated in all patient groups (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1</xref>).</p>
<p id="P15">Furthermore, pathway enrichment analysis showed modulation, to varying extents (<xref ref-type="fig" rid="F3">Figure 3</xref>), of several overlapping pathways among mildly, moderately, and severely affected patients (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1</xref>). In addition to upregulation of immune-related response genes, there was consistent disruption of the ribosome pathway. The SARS-CoV-2 receptor ACE2 is an interferon-regulated gene and is upregulated in response to SARS-CoV-2 infection.<sup>
<xref ref-type="bibr" rid="R25">25</xref>
</sup> We also found that ACE2 expression was highest in patients with severe disease compared to patients with mild and moderate disease (<xref ref-type="fig" rid="F3">Figure 3</xref>).</p>
</sec>
<sec id="S10">
<title>Comparison of functional enrichment among patients with mild, moderate, and severe COVID-19</title>
<p id="P16">To further delineate the differences among these groups, we compared the expression levels of genes and associated pathways (complement and coagulation cascades, cytokine-cytokine receptor interaction, JAK STAT signaling, TGF beta signaling pathway, platelets activation and ribosome pathway) between patients with mild, moderate, and severe disease. Gene expression in most regulated pathways was significantly higher (adj <italic>p</italic>-value &lt; 0.05) in patients with severe disease compared to those with mild or moderate disease (<xref ref-type="fig" rid="F3">Figure 3</xref>). For example, expression of certain interleukins (such as <italic>IL11</italic>, <italic>IL12</italic>, <italic>IL19</italic>, <italic>IL34</italic>), interleukin receptors (like <italic>IL10RA</italic>, <italic>IL21R</italic> and <italic>IL11RA</italic>), chemokines and tumour necrosis factor genes (such as <italic>CXCL12</italic>, <italic>CXCL9</italic>, <italic>CCL25</italic>, <italic>CCL2</italic>, <italic>CCR5</italic>, <italic>CCR7</italic>, <italic>TNFSF9</italic>, <italic>TNFSF15</italic>, <italic>TNFRSF25</italic> and <italic>TNFRSF9</italic>) were significantly higher in patients with severe disease compared to patients with mild or moderate disease (adj <italic>p</italic>-value &lt; 0.05; <xref ref-type="fig" rid="F3">Figure 3</xref>). Furthermore, complement and coagulation cascades (e.g. <italic>C2</italic>, <italic>C5</italic>, <italic>C6</italic>, <italic>F12</italic> and <italic>F8</italic>) were activated to a higher extent in patients with severe disease. Finally, patients with severe disease had higher expression of <italic>STAT4</italic>, <italic>STAT5A</italic> and <italic>STAT5B</italic> which are important components of JAK-STAT pathway and play a critical role in the fate of T helper cells<sup>
<xref ref-type="bibr" rid="R26">26</xref>
</sup>.</p>
<p id="P17">The highest fold change (&gt; 2) in patients with severe disease was among the proinflammatory cytokines and chemokine receptors <italic>CCR1</italic> (CXCL8/CXCL6 receptor), <italic>CCR6</italic>, <italic>CCR22</italic>, <italic>CCR25</italic>, <italic>IL3RA</italic>, <italic>IL11</italic>, <italic>IL19</italic>, and <italic>IL21RA</italic>, the TGF-β signaling genes <italic>BMP2</italic>, <italic>BMP7</italic>, <italic>PDGFA</italic>, and <italic>TNFSF11</italic>, and the complement and platelet cascade genes <italic>C6</italic>, <italic>C7</italic>, <italic>F2</italic>, <italic>F5</italic>, <italic>SERPINC1</italic>, and <italic>SERPIND1</italic> (<xref ref-type="fig" rid="F4">Figure 4</xref>). This distinction is likely due to viral infection resulting in release of inflammatory responses to a higher extent in patients with severe disease as compared to patients with mild or moderate disease.</p>
<p id="P18">Finally, we compared transcriptomic changes in male and female COVID-19 patients with mild and moderate outcomes. Several immune related genes (<italic>CSF2</italic>, <italic>TNFSF11</italic>, <italic>TNFRSF11B</italic>, <italic>IL18R1</italic>, <italic>IFIT1B</italic> and <italic>C4BPA</italic>) were upregulated in male patients compared to females (<xref ref-type="fig" rid="F5">Figure 5</xref>).</p>
</sec>
</sec>
<sec id="S11" sec-type="discussion">
<title>Discussion</title>
<p id="P19">Transcriptomic analysis of nasopharyngeal tissues from patients with COVID-19 reveals a robust early induction of cytokine and immune-related profiles by SARS-CoV-2 infection. In addition, elevated levels of complement and coagulation cascades were seen. Our findings are similar to those recently observed by Butler et al.<sup>
<xref ref-type="bibr" rid="R27">27</xref>
</sup> in New York (United States) and Qin et al.<sup>
<xref ref-type="bibr" rid="R28">28</xref>
</sup> in Wuhan (China). The latter work reported that an increase in ‘serum’ cytokine and chemokine levels, as well as in neutrophil-lymphocyte-ratio (NLR) in SARS-CoV-2 infected patients is correlated with the severity of the disease and adverse outcomes, suggesting a role for hyper-inflammatory responses in COVID-19 pathogenesis. Similarly, inflammationinduced coagulation pathways, which can themselves be regulated by the complement system, are pivotal in controlling pathogenesis associated with infections.<sup>
<xref ref-type="bibr" rid="R29">29</xref>
</sup>
</p>
<p id="P20">Our RNA work, using nasopharyngeal tissue, extends those findings to show that those pathways are more significantly altered in patients with severe disease outcomes. Specifically, SARS-CoV-2 seems to induce expression of certain genes (<xref ref-type="fig" rid="F4">Figure 4</xref>) to higher extents in patients with severe, compared to those with mild or moderate disease. This finding has direct prognostic and therapeutic implications. Identifying molecules targeting the pathways where those genes are involved might help ameliorate or avoid adverse clinical outcomes due to SARS-CoV-2. Moreover, this early expression signature can be used to predict the clinical course of disease, so that required early interventions can be implemented. However, larger datasets are needed to validate this expression signature and to show that it can reliably predict disease outcomes in the general population.</p>
<p id="P21">Certain molecular pathways require specific attention. In the majority of patients with COVID-19, respiratory failure is the primary cause of death and is often associated with uncontrolled inflammatory responses, edema, and lung fibrosis.<sup>
<xref ref-type="bibr" rid="R30">30</xref>
</sup> This lung fibrosis is mainly triggered by transforming growth factor-beta (TGF-β).<sup>
<xref ref-type="bibr" rid="R10">10</xref>
</sup> In our analysis, the TGF-β pathway was significantly upregulated in patients with severe disease suggesting they are more prone to respiratory failure. The PI3K/Akt and JAK/STAT signaling pathways are two other noteworthy pathways given that several cellular and immune responses, including host cell immune response to counteract viral infection <sup>
<xref ref-type="bibr" rid="R31">31</xref>
</sup>, activation of interferon-stimulated genes (ISGs) <sup>
<xref ref-type="bibr" rid="R32">32</xref>
</sup>, and activation of several regulatory and pro-inflammatory cytokines<sup>
<xref ref-type="bibr" rid="R33">33</xref>
</sup> converge on those two pathways.</p>
<p id="P22">Our gender-specific transcriptomic analysis revealed a few genes which were upregulated in male patients compared to females (<xref ref-type="fig" rid="F5">Figure 5</xref>). It is highly likely that many other key factors, which are involved in sex-specific responses to SARS-CoV-2, were not detected in our study. It is possible that our cohort was not large enough to perform appropriate comparisons on a large number of patients adequately stratified for age, sex, and disease severity.</p>
<p id="P23">Taken together, our study highlights key molecular and functional pathways involved in COVID-19 pathogenesis and characterizes a specific early expression signature associated with severe disease outcomes due to SARS-CoV-2.</p>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplementary Figure 1</label>
<caption>
<p id="P24">Dotplot visualization of upregulated (a), and downregulated pathways (b) in patients with mild, moderate and severe disease. The color of the dots represents adj p-value for each enriched pathways, and size represents the percentage of genes enriched in the total gene set. Volcano plots for upregulated and downregulated genes in patient with mild (c), moderate (d), and severe (e) outcomes. X-axis represents log2 fold change of genes and y axis represents –log<sub>10</sub> P-value in DEG analysis.</p>
</caption>
<media xlink:href="EMS96492-supplement-Supplementary_Figure_1.JPG" mimetype="image" mime-subtype="jpeg" id="N66506" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD2">
<label>Supplemental Table 1</label>
<media xlink:href="EMS96492-supplement-Supplemental_Table_1.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="N66515" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<fn-group>
<fn id="FN1" fn-type="conflict">
<p id="P25">
<bold>Financial Support and Competing Interests Statement</bold>
</p>
<p id="P26">his work was supported by internal funds from the College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences. Authors have no conflicts of interest to disclose.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="web">
<collab>Johns Hopkins Center for Systems Sciences and Engineering</collab>
<article-title>COVID-19 Dashboard</article-title>
<year>2020</year>
<comment>
<ext-link ext-link-type="uri" xlink:href="https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6">https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group>
<article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>
<source>The Lancet</source>
<year>2020</year>
<volume>395</volume>
<fpage>497</fpage>
<lpage>506</lpage>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guan</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>ZY</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Ou</surname>
<given-names>CQ</given-names>
</name>
<name>
<surname>He</surname>
<given-names>JX</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Hui</surname>
<given-names>DSC</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>Clinical Characteristics of Coronavirus Disease 2019 in China</article-title>
<source>N Engl J Med</source>
<year>2020</year>
<volume>382</volume>
<fpage>1708</fpage>
<lpage>1720</lpage>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uddin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mustafa</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Rizvi</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Loney</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Suwaidi</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Al-Marzouqi</surname>
<given-names>AHH</given-names>
</name>
<name>
<surname>Eldin</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Alsabeeha</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Adrian</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Stefanini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nowotny</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions</article-title>
<source>Viruses</source>
<year>2020</year>
<volume>12</volume>
<fpage>526</fpage>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>vom Steeg</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>SL</given-names>
</name>
</person-group>
<article-title>SeXX Matters in Infectious Disease Pathogenesis</article-title>
<source>PLoS Pathog</source>
<year>2016</year>
<volume>12</volume>
<fpage>e1005374</fpage>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>
<article-title>Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: A retrospective study of 168 severe patients</article-title>
<source>PLoS Pathog</source>
<year>2020</year>
<volume>16</volume>
<fpage>e1008520</fpage>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fehr</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Channappanavar</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus</article-title>
<source>Annu Rev Med</source>
<year>2017</year>
<volume>68</volume>
<fpage>387</fpage>
<lpage>399</lpage>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Newton</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Cardani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Braciale</surname>
<given-names>TJ</given-names>
</name>
</person-group>
<article-title>The host immune response in respiratory virus infection: balancing virus clearance and immunopathology</article-title>
<source>Semin Immunopathol</source>
<year>2016</year>
<volume>38</volume>
<fpage>471</fpage>
<lpage>482</lpage>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Wit</surname>
<given-names>E</given-names>
</name>
<name>
<surname>van Doremalen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Falzarano</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Munster</surname>
<given-names>VJ</given-names>
</name>
</person-group>
<article-title>SARS and MERS: recent insights into emerging coronaviruses</article-title>
<source>Nat Rev Microbiol</source>
<year>2016</year>
<volume>14</volume>
<fpage>523</fpage>
<lpage>534</lpage>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiong</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients</article-title>
<source>Emerg Microbes Infect</source>
<year>2020</year>
<volume>9</volume>
<fpage>761</fpage>
<lpage>770</lpage>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lieberman</surname>
<given-names>NAP</given-names>
</name>
<name>
<surname>Peddu</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shrestha</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Mears</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Cajimat</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Bente</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>PY</given-names>
</name>
<name>
<surname>Bovier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Roychoudhury</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>
<article-title>In vivo antiviral host response to SARS-CoV-2 by viral load, sex, and age</article-title>
<source>bioRxiv</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.06.22.165225</pub-id>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abou Tayoun</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Loney</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Khansaheb</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ramaswamy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Harilal</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Deesi</surname>
<given-names>ZO</given-names>
</name>
<name>
<surname>Varghese</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Suwaidi</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Alkhajeh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>AlDabal</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Uddin</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Genomic surveillance and phylogenetic analysis reveal multiple introductions of SARS-CoV-2 into a global travel hub in the Middle East</article-title>
<source>bioRxiv</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.05.06.080606</pub-id>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harilal</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ramaswamy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Loney</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Al Suwaidi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Khansaheb</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Alkhaja</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Varghese</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Deesi</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Nowotny</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Alsheikh-Ali</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tayoun</surname>
<given-names>AA</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 Whole Genome Amplification and Sequencing for Effective Population-Based Surveillance and Control of Viral Transmission</article-title>
<source>Clin Chem</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1093/clinchem/hvaa187</pub-id>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alm</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Broberg</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Connor</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hodcroft</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Komissarov</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Maurer-Stroh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Melidou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Neher</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>O'Toole</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pereyaslov</surname>
<given-names>D</given-names>
</name>
<collab>laboratories WHOERs, group GE, laboratories WHOERs, group* GE</collab>
</person-group>
<article-title>Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020</article-title>
<source>Euro Surveill</source>
<year>2020</year>
<volume>25</volume>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="web">
<person-group person-group-type="author">
<name>
<surname>Andrews</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>FastQC: a quality control tool for high throughput sequence data</article-title>
<year>2010</year>
<comment>Available online at: <ext-link ext-link-type="uri" xlink:href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc">http://www.bioinformatics.babraham.ac.uk/projects/fastqc</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ewels</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Magnusson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lundin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Käller</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>MultiQC: summarize analysis results for multiple tools and samples in a single report</article-title>
<source>Bioinformatics</source>
<year>2016</year>
<volume>32</volume>
<fpage>3047</fpage>
<lpage>3048</lpage>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Langmead</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Salzberg</surname>
<given-names>SL</given-names>
</name>
</person-group>
<article-title>HISAT: a fast spliced aligner with low memory requirements</article-title>
<source>Nat Methods</source>
<year>2015</year>
<volume>12</volume>
<fpage>357</fpage>
<lpage>360</lpage>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="http://broadinstitute.github.io/picard/">http://broadinstitute.github.io/picard/</ext-link>
</p>
</note>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Smyth</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>featureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title>
<source>Bioinformatics</source>
<year>2013</year>
<volume>30</volume>
<fpage>923</fpage>
<lpage>930</lpage>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Love</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Anders</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>
<source>Genome Biol</source>
<year>2014</year>
<volume>15</volume>
<fpage>550</fpage>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>He</surname>
<given-names>QY</given-names>
</name>
</person-group>
<article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title>
<source>OMICS</source>
<year>2012</year>
<volume>16</volume>
<fpage>284</fpage>
<lpage>287</lpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://software.broadinstitute.org/morpheus/">https://software.broadinstitute.org/morpheus/</ext-link>
</p>
</note>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goedhart</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Luijsterburg</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>VolcaNoseR – a web app for creating, exploring and sharing volcano plots</article-title>
<source>bioRxiv</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.05.07.082263</pub-id>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="web">
<article-title>GraphPad Prism version 8.00 for Windows, GraphPad Software, La Jolla California USA</article-title>
<comment>
<ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com">www.graphpad.com</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ziegler</surname>
<given-names>CGK</given-names>
</name>
<name>
<surname>Allon</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Nyquist</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Mbano</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>VN</given-names>
</name>
<name>
<surname>Tzouanas</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yousif</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Bals</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hauser</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>
<email>lung-network@humancellatlas.org</email> HCALBNEa, Network HCALB: SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues</article-title>
<source>Cell</source>
<year>2020</year>
<volume>181</volume>
<fpage>1016</fpage>
<lpage>1035</lpage>
<comment>e1019</comment>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seif</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Khoshmirsafa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Aazami</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mohsenzadegan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sedighi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bahar</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells</article-title>
<source>Cell Commun Signal</source>
<year>2017</year>
<volume>15</volume>
<fpage>23</fpage>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butler</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Mozsary</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Meydan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Danko</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Foox</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rosiene</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shaiber</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Afshinnekoo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>MacKay</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sedlazeck</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Ivanov</surname>
<given-names>NA</given-names>
</name>
<etal/>
</person-group>
<article-title>Shotgun Transcriptome and Isothermal Profiling of SARS-CoV-2 Infection Reveals Unique Host Responses, Viral Diversification, and Drug Interactions</article-title>
<source>bioRxiv</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.04.20.048066</pub-id>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>DS</given-names>
</name>
<etal/>
</person-group>
<article-title>Dysregulation of Immune Response in Patients with Coronavirus 2019 (COVID-19) in Wuhan, China</article-title>
<source>Clin Infect Dis</source>
<year>2020</year>
<volume>71</volume>
<fpage>762</fpage>
<lpage>768</lpage>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramlall</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Thangaraj</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Meydan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Foox</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J</given-names>
</name>
<name>
<surname>May</surname>
<given-names>B</given-names>
</name>
<name>
<surname>De Freitas</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Glicksberg</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Mason</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Tatonetti</surname>
<given-names>NP</given-names>
</name>
<etal/>
</person-group>
<article-title>Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection</article-title>
<source>Nature Medicine</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1038/s41591-020-1021-2</pub-id>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Pathological findings of COVID-19 associated with acute respiratory distress syndrome</article-title>
<source>The Lancet Respiratory Medicine</source>
<year>2020</year>
<volume>8</volume>
<fpage>420</fpage>
<lpage>422</lpage>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diehl</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Schaal</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Make yourself at home: viral hijacking of the PI3K/Akt signaling pathway</article-title>
<source>Viruses</source>
<year>2013</year>
<volume>5</volume>
<fpage>3192</fpage>
<lpage>3212</lpage>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ezell</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Polytarchou</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hatziapostolou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sanidas</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bihani</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Comb</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Sourvinos</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tsichlis</surname>
<given-names>PN</given-names>
</name>
</person-group>
<article-title>The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2012</year>
<volume>109</volume>
<fpage>E613</fpage>
<lpage>621</lpage>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Villarino</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Kanno</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ferdinand</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>O'Shea</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>Mechanisms of Jak/STAT signaling in immunity and disease</article-title>
<source>J Immunol</source>
<year>2015</year>
<volume>194</volume>
<fpage>21</fpage>
<lpage>27</lpage>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Schematic workflow for Transcriptomic analysis. Sequencing data underwent preprocessing which includes primary QC and read mapping, followed by differenticially expressed genes (DEG) analysis and downstream pathway enrichment analysis and visualization.</p>
</caption>
<graphic xlink:href="EMS96492-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>
<italic>Left</italic>, Dotplot visualization of enriched Pathway terms in all COVID-19 patients. The color of the dots represents adj <italic>p</italic>-value for each enriched pathway, and size represents the percentage of genes enriched in the total gene set. <italic>Right</italic>, Volcano plot representing upregulated and downregulated genes. X-axis represents log<sub>2</sub> fold change of genes and Y-axis represents –log<sub>10</sub> <italic>P</italic>-value in differentially expressed gene (DEG) analysis.</p>
</caption>
<graphic xlink:href="EMS96492-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>Heat map and Violin plots of pathways in patients with mild, moderate or severe disease. Pathways are: a) Complement and coagulation cascades, Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, d) TGF-beta signalling, Platelets activation, and Ribosome. Heat map depicts the log<sub>2</sub> fold change of differentially expressed gene (DEGs) of COVID-19 patients compared with controls. Genes included have a log<sub>2</sub> fold change of more than 1 and a <italic>p</italic>-adjusted value of less than 0.05. For every gene in a given pathway, the average counts per million (CPM) was calculated in cases with mild, moderate and severe disease and these CPM values were plotted (Violin plots) indicating median and quartiles as well as minima and maxima bounds. *Expression of <italic>ACE2</italic> and <italic>TMPRSS2</italic>.</p>
</caption>
<graphic xlink:href="EMS96492-f003"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p>Scatter plot of fold change gene expression differences between patients with mild/moderate and severe outcomes. Fold change of mild/moderate was averaged and subtracted from severe fold change when compared to controls.</p>
</caption>
<graphic xlink:href="EMS96492-f004"/>
</fig>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<p>Heat map (top) and Violin plots (bottom) of differentially expressed genes in males and females. Heat map depicts the log<sub>2</sub> fold change of differentially expressed gene (DEGs) of COVID-19 patients compared with controls. Genes included have a log<sub>2</sub> (fold change) of more than 1 and adj <italic>p</italic>-value &lt; 0.05. Violin plots represent median and 75th quartiles as well as minima and maxima bounds of CPM (counts per million) of highlighted differentially regulated genes.</p>
</caption>
<graphic xlink:href="EMS96492-f005"/>
</fig>
<table-wrap id="T1" position="float" orientation="portrait">
<label>Table 1</label>
<caption>
<title>Clinical Characteristics of COVID-19 patients in this study</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="center" valign="middle" rowspan="2">Characteristic</th>
<th align="center" valign="middle" rowspan="2">All Patients (N=50)</th>
<th align="center" valign="middle" colspan="3">Stratified by Disease Severity</th>
</tr>
<tr>
<th align="center" valign="middle">Asymptomatic/Mild (N=37)</th>
<th align="center" valign="middle">Moderate (N=10)</th>
<th align="center" valign="middle">Severe/Critical (N=3)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" valign="middle">Age Mean (SD), yr</td>
<td align="center" valign="middle">40.92 (16.03)</td>
<td align="center" valign="middle">36.4 (14.04)</td>
<td align="center" valign="middle">49.28 (14.35)</td>
<td align="center" valign="middle">68 (3.56)</td>
</tr>
<tr>
<td align="center" valign="middle">Female Sex - no./total no. (%)</td>
<td align="center" valign="middle">18/50 (36%)</td>
<td align="center" valign="middle">16/37 (43.24%)</td>
<td align="center" valign="middle">1/10 (10%)</td>
<td align="center" valign="middle">1/3 (33.33%)</td>
</tr>
<tr>
<td align="center" valign="middle">Body Mass (kg) - Mean (SD)</td>
<td align="center" valign="middle">66.2 (30.84)</td>
<td align="center" valign="middle">63.4 (28.65)</td>
<td align="center" valign="middle">73.07 (41.83)</td>
<td align="center" valign="middle">77.93 (8.29)</td>
</tr>
<tr>
<td align="center" valign="middle">Current Smoker - no./total no. (%)</td>
<td align="center" valign="middle">0/50 (0%)</td>
<td align="center" valign="middle">0/37 (0%)</td>
<td align="center" valign="middle">0/10 (0%)</td>
<td align="center" valign="middle">0/3 (0%)</td>
</tr>
<tr>
<td align="center" valign="middle">
<bold>Coexisting Disorder - no./total no. (%)</bold>
</td>
<td align="center" valign="middle" colspan="4"/>
</tr>
<tr>
<td align="center" valign="middle">Chronic Cardiac Disease (not Hypertension)</td>
<td align="center" valign="middle">3/50 (6%)</td>
<td align="center" valign="middle">1/37 (2.7%)</td>
<td align="center" valign="middle">2/10 (20%)</td>
<td align="center" valign="middle">0/3 (0%)</td>
</tr>
<tr>
<td align="center" valign="middle">Hypertension</td>
<td align="center" valign="middle">9/50 (18%)</td>
<td align="center" valign="middle">5/37 (13.51%)</td>
<td align="center" valign="middle">3/10 (30%)</td>
<td align="center" valign="middle">1/3 (33.33%)</td>
</tr>
<tr>
<td align="center" valign="middle">Chronic Pulmonary Disease</td>
<td align="center" valign="middle">0/50 (0%)</td>
<td align="center" valign="middle">0/37 (0%)</td>
<td align="center" valign="middle">0/10 (0%)</td>
<td align="center" valign="middle">0/3 (0%)</td>
</tr>
<tr>
<td align="center" valign="middle">Asthma</td>
<td align="center" valign="middle">0/50 (0%)</td>
<td align="center" valign="middle">0/37 (0%)</td>
<td align="center" valign="middle">0/10 (0%)</td>
<td align="center" valign="middle">0/3 (0%)</td>
</tr>
<tr>
<td align="center" valign="middle">Chronic kidney disease</td>
<td align="center" valign="middle">1/50 (2%)</td>
<td align="center" valign="middle">0/37 (0%)</td>
<td align="center" valign="middle">0/10 (0%)</td>
<td align="center" valign="middle">1/3 (33.33%)</td>
</tr>
<tr>
<td align="center" valign="middle">Chronic liver disease</td>
<td align="center" valign="middle">0/50 (0%)</td>
<td align="center" valign="middle">0/37 (0%)</td>
<td align="center" valign="middle">0/10 (0%)</td>
<td align="center" valign="middle">0/3 (0%)</td>
</tr>
<tr>
<td align="center" valign="middle">Chronic Neurological Disorder</td>
<td align="center" valign="middle">0/50 (0%)</td>
<td align="center" valign="middle">0/37 (0%)</td>
<td align="center" valign="middle">0/10 (0%)</td>
<td align="center" valign="middle">0/3 (0%)</td>
</tr>
<tr>
<td align="center" valign="middle">Diabetes Mellitus</td>
<td align="center" valign="middle">8/50 (16%)</td>
<td align="center" valign="middle">3/37 (8.1%)</td>
<td align="center" valign="middle">3/10 (30%)</td>
<td align="center" valign="middle">2/3 (66.66%)</td>
</tr>
<tr>
<td align="center" valign="middle">Malignant Neoplasms</td>
<td align="center" valign="middle">0/50 (0%)</td>
<td align="center" valign="middle">0/37 (0%)</td>
<td align="center" valign="middle">0/10 (0%)</td>
<td align="center" valign="middle">0/3 (0%)</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
